Status:
RECRUITING
Targeted Α-synuclein PET Imaging in the Diagnosis of Multiple System Atrophy
Lead Sponsor:
Min Zhao,MD
Conditions:
Multiple System Atrophy - Cerebellar Subtype (MSA-C)
Multiple System Atrophy - Parkinsonian Subtype (MSA-P)
Eligibility:
All Genders
35-80 years
Brief Summary
The aim of this study was to apply the targeted α-synuclein PET study technique to investigate the pathological load and spatial distribution characteristics of α-syn in MSA patients, and to assess it...
Eligibility Criteria
Inclusion
- Age\> 35 years old, gender is not limited;
- Clinically confirmed MSA and clinically probable MSA according to the 2022 MDS MSA diagnostic criteria;
- all patients had been ruled out of polyQ disease by genetic testing;
- Voluntarily participate in this study and sign the informed consent form.
Exclusion
- pregnancy or breastfeeding;
- contraindications to MRI examination or inability to cooperate in completing neuroimaging examination;
- previous history of other neurological disorders or presence of other organic intracranial lesions on neuroimaging that cannot be interpreted by MSA, such as epilepsy, trauma, tumors, or high-grade cerebral white matter degeneration (Fazekas grade 2 and above);
- History of alcohol or drug abuse
Key Trial Info
Start Date :
September 14 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2026
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT06890377
Start Date
September 14 2024
End Date
March 31 2026
Last Update
March 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Third Xiangya Hospital of Central South University
Hunan, Changsha, China, 410000